Clinical trials: Circulating Tumor Cell
Non-small-cell Lung Carcinoma
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The…
- Trial name
- NCT02647164
- Volunteers
- 360 people
- Sponsor
- GenoSaber
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Circulating Tumor Cells (CTCs)
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and…
- Trial name
- NCT02904135
- Where
- Taiwan
- Volunteers
- 141 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal…
- Conditions
- Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
- Trial name
- CheckMate 9TN (NCT03770299)
- Testing
- Nivolumab, Vinorelbine, Gemcitabine
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship.
- Trial name
- NCT03483922
- Testing
- ctDNA methylation in and it's Correlation wth Development and prediction of HCC
- Where
- Bangladesh
- Volunteers
- 403 people
- Sponsor
- HKGepitherapeutics
Primary Lung Cancer
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer.
- Trial name
- LDx (NCT01830426)
- Where
- 3 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Epic Sciences
Circulating Tumor Cells (CTCs)
Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer
To address the challenges of isolating and analyzing rare cells, this study aims to validate technical diagnostic instrumentation, tests, protocols and analysis to correlate the number of circulating tumor cells present in whole…
- Trial name
- NCT02904161
- Where
- Taiwan
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- MiCareo Taiwan Co., Ltd.
NSCLC (Non-small Cell Lung Cancer)
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
This is a multicentre, prospective, study of EGFR )Epidermal Growth Factor Receptor) mutation status in advanced NSCLC (Non-small cell lung cancer)patients (locally advanced and/or metastatic disease) with adenocarcinoma…
- Trial name
- CONCORDANCE (NCT03562819)
- Where
- 14 sites in India
- Volunteers
- 268 people
- Sponsor
- AstraZeneca
Circulating Tumor DNA, Cancer
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has…
- Conditions
- Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing
- Trial name
- NCT02620527
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Foundation Medicine
Metastatic Breast Cancer
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Utilizing CellSearch® technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine sensitivity (estrogen receptor [ER] and Bcl-2) and…
- Trial name
- COMETI P2 (NCT01701050)
- Testing
- Blood collection
- Where
- 20 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Janssen Diagnostics, LLC
Non-small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2.
- Trial name
- NCT02029209
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Circulating Tumor Cells.Breast
The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now.
- Trial name
- NCT03006055
- Testing
- Circulating tumor cells
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Beijing Viroad Biotechnology Co., Ltd.
Hepatocellular Carcinoma
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC.
- Trial name
- NCT05823584
- Where
- Taiwan
- Volunteers
- 207 people
- Sponsor
- TCM Biotech International Corp.
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Neoplasms, Breast
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
The underlying biology of the various patterns of metastasis observed in different tumour types remains unclear. The detection and characterization of circulating tumour cells in cancer patients has provided important new…
- Trial name
- NCT00820924
- Testing
- LAPATINIB
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Solitary Pulmonary Nodule
Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules
By testing the CTC number of new solitary pulmonary nodule patient, evaluating the correlation of CTC number and benign and malignant lung nodules auxiliary diagnosis, the correlation of CTC number and the size of lung nodules of…
- Trial name
- NCT02653859
- Volunteers
- 50 people
- Sponsor
- GenoSaber
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Metastatic Breast Cancer
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
- Trial name
- ACT-MBC (NCT05662345)
- Testing
- CellSearch Circulating Tumor Cells
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Menarini Silicon Biosystems, INC
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics